Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 2/20 | 0.57 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.57 |
| ▸ | PTGS2 known ✓ | P35354 | 2/20 | 0.57 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.57 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.57 |
| ▸ | ACE known ✓ | P12821 | 1/20 | 0.54 |
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.51 |
| ▸ | ESR1 known ✓ | P03372 | 2/20 | 0.51 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.51 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.51 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.51 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.51 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.51 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.51 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.51 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.51 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.51 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.51 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.51 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL31607501 | 1.00 | KDM6B (0.58) | KDM6BALOX15HIF1AHSD17B10KDM4E | |
| Water SCHEMBL17747948 | 1.00 | KDM6B (0.58) | KDM6BALOX15HIF1AHSD17B10KDM4E | |
| Water SCHEMBL31413328 | 1.00 | KDM6B (0.58) | KDM6BALOX15HIF1AHSD17B10KDM4E | |
| Water SCHEMBL31482262 | 1.00 | KDM6B (0.58) | KDM6BALOX15HIF1AHSD17B10KDM4E | |
| Hydrochloric Acid SCHEMBL6825737 | 0.98 | KDM6B (0.57) | KDM6BALOX15HIF1AHSD17B10KDM4E | |
| SCHEMBL8470026 | 0.98 | KDM6B (0.60) | KDM6BALOX15HIF1AHSD17B10KDM4E | |
| SCHEMBL2283369 | 0.98 | KDM6B (0.60) | KDM6BALOX15HIF1AHSD17B10KDM4E | |
| SCHEMBL34002 | 0.98 | KDM6B (0.60) | KDM6BALOX15HIF1AHSD17B10KDM4E | |
| Hydrochloric Acid SCHEMBL29670211 | 0.97 | KDM6B (0.58) | KDM6BALOX15HIF1AHSD17B10KDM4E | |
| Hydrochloric Acid SCHEMBL523205 | 0.97 | KDM6B (0.58) | KDM6BALOX15HIF1AHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230324359-A1 | THERAPEUTIC DRUG FOR LIPID-PEROXIDATION-INDUCED DISEASES AND SCREENING METHOD FOR THERAPEUTIC DRUGS FOR LIPID-PEROXIDATION-INDUCED DISEASES | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2023-10-12 | — | — | US | claimed |
| US-20220096410-A1 | PHARMACEUTICAL COMPOSITION FOR INTRAOCULAR OR ORAL ADMINISTRATION FOR TREATMENT OF RETINAL DISEASES | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2022-03-31 | — | — | US | claimed |
| US-20220023283-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DEMENTIA AND CEREBROVASCULAR DISORDERS | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2022-01-27 | — | — | US | claimed |
| US-12564596-B2 | Agents and methods for modulating pathogen activity | GRIFFITH UNIVERSITY (AU) | 2026-03-03 | — | — | US | disclosed |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| US-12306164-B2 | Therapeutic drug for lipid-peroxidation-induced diseases and screening method for therapeutic drugs for lipid-peroxidation-induced diseases | Yamamada, Ken-Ichi (JP) | 2025-05-20 | — | — | US | disclosed |
| CN-119510740-A | Therapeutic agent for lipid peroxidation-induced disease and screening method therefor | 扶桑药品工业株式会社 | 2025-02-25 | — | — | CN | disclosed |
| CN-118986994-A | Agents and methods for modulating pathogen activity | 格里菲斯大学 | 2024-11-22 | — | — | CN | disclosed |
| CN-113164494-B | Agents and methods for modulating pathogen activity | 格里菲斯大学 | 2024-08-27 | — | — | CN | disclosed |
| EP-4295864-A2 | PHENYLPROPIONIC ACID DERIVATIVES FOR MODULATING PATHOGEN ACTIVITY | Research Institute at Nationwide Children's Hospital (US) | 2023-12-27 | — | — | EP | disclosed |
| EP-3856196-B1 | PHENYLPROPIONIC ACID DERIVATIVES FOR MODULATING PATHOGEN ACTIVITY | UNIV GRIFFITH (AU) | 2023-11-15 | — | — | EP | disclosed |
| CN-116626281-A | Digitoxin detection kit | 北京九强生物技术股份有限公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-115850105-B | Co-crystal of methyldopa and proline as well as preparation method and application thereof | 浙江野风药业股份有限公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-115850105-A | Co-crystal of methyldopa and proline, and preparation method and application thereof | 浙江野风药业股份有限公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-115745821-A | Methyldopa anhydrous crystal form, solvate and preparation method thereof | 浙江野风药业股份有限公司 | 2023-03-07 | — | — | CN | disclosed |
| CN-115745821-A | Methyldopa anhydrous crystal form, solvate and preparation method thereof | 浙江野风药业股份有限公司 | 2023-03-07 | — | — | CN | disclosed |
| US-11519893-B2 | Therapeutic drug for lipid-peroxidation-induced diseases and screening method for therapeutic drugs for lipid-peroxidation-induced diseases | YAMADA, Ken-ichi (JP) | 2022-12-06 | — | — | US | disclosed |
| US-20220096410-A1 | PHARMACEUTICAL COMPOSITION FOR INTRAOCULAR OR ORAL ADMINISTRATION FOR TREATMENT OF RETINAL DISEASES | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2022-03-31 | — | — | US | disclosed |
| US-11246873-B2 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-15 | — | — | US | disclosed |
| US-20220023283-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DEMENTIA AND CEREBROVASCULAR DISORDERS | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11519893-B2 | Therapeutic drug for lipid-peroxidation-induced diseases and screening method for therapeutic drugs for lipid-peroxidation-induced diseases | GPX4, GPX1, ALOX15 | ADORA3 1525/4885HTR2A 3436/4885PTGS2 103/4885 |
| US-20220023283-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DEMENTIA AND CEREBROVASCULAR DISORDERS | HTR3B, HTR3A, HTR2A | ADORA3 206/4885HTR2A 3/4885PTGS2 2781/4885 |
| US-12564596-B2 | Agents and methods for modulating pathogen activity | C3AR1, HTR3A, CHRM3 | ADORA3 52/4885HTR2A 82/4885PTGS2 3340/4885 |
| US-12306164-B2 | Therapeutic drug for lipid-peroxidation-induced diseases and screening method for therapeutic drugs for lipid-peroxidation-induced diseases | GPX4, GPX1, ALOX15 | ADORA3 1525/4885HTR2A 3436/4885PTGS2 103/4885 |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | ACE2, FURIN, SARS1 | ADORA3 4081/4885HTR2A 1457/4885PTGS2 1124/4885 |
| US-20230324359-A1 | THERAPEUTIC DRUG FOR LIPID-PEROXIDATION-INDUCED DISEASES AND SCREENING METHOD FOR THERAPEUTIC DRUGS FOR LIPID-PEROXIDATION-INDUCED DISEASES | GPX4, GPX1, ALOX15 | ADORA3 1525/4885HTR2A 3436/4885PTGS2 103/4885 |
| US-20220096410-A1 | PHARMACEUTICAL COMPOSITION FOR INTRAOCULAR OR ORAL ADMINISTRATION FOR TREATMENT OF RETINAL DISEASES | MC2R, ADRA1B, MTNR1B | ADORA3 926/4885HTR2A 13/4885PTGS2 3724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.